Public Health - Newborn Screening Program - Fees and Core Conditions
HB1625 makes several changes to Maryland’s newborn screening program. It adjusts the fee-setting authority for newborn testing so that fees are set at an amount sufficient to cover the administrative, laboratory, and follow-up costs of the program, rather than being capped in the prior language. The bill also updates the list of core conditions the Department of Health must screen for to reflect the U.S. Department of Health and Human Services’ Recommended Uniform Screening Panel as of January 1, 2026.
The bill changes how Maryland responds when a new core condition is added to the national screening panel. Instead of requiring the Department to implement testing within 1 year and 6 months, the State Advisory Council on Hereditary and Congenital Disorders must first advise the Department on risks, harms, accessibility, and costs, and recommend whether testing should be implemented. After considering that advice, the Department may implement testing, delay it, or decide not to implement it. The bill also revises reporting requirements to the General Assembly when implementation is delayed or declined, and it preserves the requirement that Maryland adopt federal screening recommendations for critical congenital heart disease if issued.
In practical terms, the bill affects the Maryland Department of Health, the State Advisory Council, newborn screening laboratories, health care providers, and families of newborns. It gives the Department more discretion over when and whether to add new screening tests, while also requiring more detailed legislative reporting if implementation is postponed or rejected. The bill continues to direct screening fees into the Newborn Screening Program Fund.
The general sentiment around the bill appears favorable, as reflected by the House passage on third reading by a wide margin and the committee report of favorable with amendments. The absence of recorded committee transcript debate suggests limited publicly documented controversy in the available materials, though the amendments indicate the bill was refined during the legislative process.
The main point of contention is the balance between timely adoption of new newborn screening tests and the practical costs, risks, and logistics of implementation. Supporters of the revised language likely favored giving the Department flexibility to assess feasibility before mandating new tests, while potential critics may be concerned that allowing delays or non-implementation could slow access to potentially life-saving screening for newborns.
HB1625 amends Maryland Health-General § 13-111 governing the statewide newborn screening program. It changes the fee standard for newborn screening, updates the reference point for required core conditions to the federal Recommended Uniform Screening Panel as of January 1, 2026, and replaces the prior automatic implementation timeline for newly added core conditions with a discretionary process that includes advisory council review and Department decision-making. It also expands and clarifies reporting obligations to the General Assembly when implementation is delayed or not pursued, while preserving the Department’s authority to adopt federal recommendations for critical congenital heart disease screening.
The bill appears to have received generally favorable treatment in the House, passing third reading by a strong 116-14 vote and receiving a favorable committee report with amendments. That voting pattern suggests broad support for updating the newborn screening program, though the amendments indicate lawmakers wanted to refine the implementation process and reporting requirements. No committee transcript was provided, so the available record does not show detailed floor or committee debate.
The central issue is whether Maryland should require rapid implementation of every new condition added to the national screening panel or allow the Department of Health to weigh risks, harms, accessibility, costs, and procurement realities before acting. The bill shifts more discretion to the Department and advisory council, which may concern advocates for immediate newborn screening expansion. On the other hand, supporters likely view the change as a practical safeguard against mandates that are not yet operationally or financially ready. The fee provision may also be a point of interest because it ensures program costs are covered, which could affect providers and the program’s funding structure.